WT
MCRB icon

Whittier Trust’s Seres Therapeutics MCRB Stock Holding History

Whittier Trust’s Portfolio MCRB Stock Details MCRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-1
Closed -$11 – 1521
2025
Q2 		$11 Sell
1
-1
-50% -$9 ﹤0.01% 1509
2025
Q1 		$21 Hold
2
– – ﹤0.01% 1489
2024
Q4 		$24 Hold
2
– – ﹤0.01% 1545
2024
Q3 		$28 Hold
2
– – ﹤0.01% 1547
2024
Q2 		$21 Buy
+2
New +$33 ﹤0.01% 1514
2018
Q1 		– Sell
-5
Closed -$1K – 1334
2017
Q4 		$1K Buy
+5
New +$1.03K ﹤0.01% 1238

Other funds holding MCRB

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vontobel Holding
Vontobel Holding Zurich, Switzerland $29.1B AUM 22.79% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

Whittier Trust's MCRB Position: Q3 2025 in Review

Whittier Trust sold out of Seres Therapeutics (MCRB) in Q3 2025, closing a stake of 1 share — an estimated $11 sold.

Whittier Trust first reported a position in MCRB in Q4 2017 and held it in 6 quarters. The position peaked at $1K in Q4 2017. 32 funds tracked by Wall St. Rank hold MCRB as of Q3 2025.

  • Whittier Trust reported no remaining Seres Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Whittier Trust sold 1 Seres Therapeutics share in Q3 2025, an estimated $11.
  • Whittier Trust first reported a position in Seres Therapeutics in Q4 2017 and held it in 6 quarters.
  • Whittier Trust's Seres Therapeutics position peaked at $1K in Q4 2017.
  • 32 funds tracked by Wall St. Rank held Seres Therapeutics as of Q3 2025.

Based on Whittier Trust's 13F filing for Q3 2025, filed 31 Oct 2025.